| Previous close | 8.55 |
| Open | 8.50 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 420.00 |
| Expiry date | 2025-12-19 |
| Day's range | 8.50 - 8.55 |
| Contract range | N/A |
| Volume | |
| Open interest | 13 |
Investor's Business DailyDow Jones Futures Fall, But Nvidia Leads Techs Higher; 7 Stocks Near Buy Points
The market rally had a mixed week as breadth narrowed. Microsoft and Merck led stocks near buy points. Here's what to do.
ReutersAnalysis-Weight-loss drug forecasts jump to $150 billion as supply grows
As millions seek access to weight-loss drugs from Novo Nordisk and Eli Lilly, increasing supplies, possible wider usage and a growing number of would-be rivals are leading some experts to raise annual global sales forecasts for the treatments to about $150 billion by the early 2030s. "It is very unusual to have a medicine that is capturing the imagination of millions of people," said Michael Kleinrock, senior research director at healthcare analytics firm IQVIA Institute for Data Science. Most insurers do not cover the new therapies with low co-payments, but an unprecedented percentage of people are paying themselves or with coupons from drug manufacturers, he said.
ZacksEli Lilly (LLY) to Ramp Up Indiana Site for Mounjaro, Zepbound
Since 2020, Eli Lilly (LLY) has committed more than $18 billion to building new manufacturing sites as well as updating existing manufacturing facilities.
